Skip to main content

AAD 2025 Sanofi | Regeneron | Mar 7, 2025 - Mar 11, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • Adult Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Pediatric Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Chronic Spontaneous Urticaria

    Chronic spontaneous urticaria (CSU) is a systemic, immune-mediated disease characterized by the spontaneous appearance of wheals and/or angioedema leading to debilitating symptoms (e.g., itching and/or burning sensation). Despite a lack of known triggers, CSU can recur for 6 weeks or more resulting in substantial physical, mental, emotional, and socio-economic effects on patients’ quality of life.

  • Prurigo Nodularis

    Prurigo Nodularis (PN) is a chronic, inflammatory skin condition characterized by intense pruritus, stinging/burning, and papulonodular lesions. Uncontrolled PN can have substantial physical, mental, emotional, and socio-economic effects on patients’ quality of life.